World's Largest Pharmaceutical Chromatography Plant To Be Built in Europe
Novasep (Pompey, France) has announced an investment of €30 million into the construction of the world’s largest pharmaceutical chromatography plant.
Novasep (Pompey, France) has announced an investment of €30 million into the construction of the world’s largest pharmaceutical chromatography plant. The plant will be located on Novasep’s existing Mourenx site in France and will be used for the production of a large volume commercial API (active pharmaceutical ingredient).
The plant will be designed and planned by the company’s in-house engineers, with plans for the plant to be operational and validated within 18 months. The investment follows the projection of a rapid increase in demand for large volume, highly purified API from complex mixtures. The systems within the plant will reportedly incorporate solvent recovery systems for the recovery of 99.9% of solvents reducing environmental impacts of the plant.
"Demand for Novasep's advanced, purification-based manufacturing capabilities in the life science industries continues to increase as drugs in development and reaching the market become more complex and specific. This necessitates our third and largest global plant expansion in 2012," commented Patrick Glaser, President and CEO of Novasep." This project demonstrates the validity of the Novasep strategy which is based on the combination of synthesis, biosynthesis and purification. We thank our institutional partners for their active support and our shareholders for their strong involvement to enable this transforming project."
For more information please visit:
ref=http://www.novasep.com >www.novasep.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
